Table 1 Baseline demographics, disease characteristics, and prior therapies
Characteristic | HRD subgroupa | Overall (N = 97) | ||
|---|---|---|---|---|
Positive (n = 20) | Negative (n = 30) | Indeterminateb (n = 47) | ||
Age, median (range), y | 71 (39–87) | 66 (47–85) | 66 (50–85) | 66 (39–87) |
Sex, n (%) | ||||
 Male | 11 (55.0) | 27 (90.0) | 38 (80.9) | 76 (78.4) |
 Female | 9 (45.0) | 3 (10.0) | 9 (19.1) | 21 (21.6) |
Race, n (%) | ||||
 White | 18 (90.0) | 24 (80.0) | 32 (68.1) | 74 (76.3) |
 Black or African American | 0 | 2 (6.7) | 1 (2.1) | 3 (3.1) |
 Other | 0 | 1 (3.3) | 2 (4.3) | 3 (3.1) |
 Unknown | 2 (10.0) | 3 (10.0) | 12 (25.5) | 17 (17.5) |
ECOG PS, n (%) | ||||
 0 | 6 (30.0) | 9 (30.0) | 14 (29.8) | 29 (29.9) |
 1 | 14 (70.0) | 20 (66.7) | 32 (68.1) | 66 (68.0) |
 2c | 0 | 1 (3.3) | 1 (2.1) | 2 (2.1) |
Histology, n (%) | ||||
 Urothelial | 14 (70.0) | 25 (83.3) | 30 (63.8) | 69 (71.1) |
 Urothelial with variant | 5 (25.0) | 2 (6.7) | 7 (14.9) | 14 (14.4) |
 Unknown | 1 (5.0) | 3 (10.0) | 10 (21.3) | 14 (14.4) |
Tumor location in bladder, n (%) | ||||
 Lower tract | 17 (85.0) | 22 (73.3) | 37 (78.7) | 76 (78.4) |
 Upper tract | 3 (15.0) | 8 (26.7) | 10 (21.3) | 21 (21.6) |
No. of prior therapies, n (%) | ||||
 1 | 11 (55.0) | 16 (53.3) | 26 (55.3) | 53 (54.6) |
 2 | 9 (45.0) | 14 (46.7) | 21 (44.7) | 44 (45.4) |
Prior therapies, n (%)d | ||||
 Cisplatin-based chemotherapy | 13 (65.0) | 20 (66.7) | 26 (55.3) | 59 (60.8) |
 Carboplatin-based chemotherapy | 5 (25.0) | 8 (26.7) | 21 (44.7) | 34 (35.1) |
 Immune checkpoint inhibitor | 14 (70.0) | 23 (76.7) | 34 (72.3) | 71 (73.2) |
 Platinum-based chemotherapy and immune checkpoint inhibitor | 12 (60.0) | 21 (70.0) | 34 (72.3) | 67 (69.1) |
 Cystectomy/nephroureterectomy | 8 (40.0) | 17 (56.7) | 22 (46.8) | 47 (48.5) |
Time from prior systemic therapy, n (%) | ||||
  <3 months | 15 (75.0) | 18 (60.0) | 27 (57.4) | 60 (61.9) |
  ≥3 months | 5 (25.0) | 12 (40.0) | 20 (42.6) | 37 (38.1) |
De novo metastases, n (%) | 12 (60.0) | 6 (20.0) | 12 (25.5) | 30 (30.9) |
Site of metastases, n (%)d | ||||
 Nodal metastases | 3 (15.0) | 7 (23.3) | 14 (29.8) | 24 (24.7) |
 Visceral metastases | 9 (45.0) | 20 (66.7) | 23 (48.9) | 52 (53.6) |
 Liver metastases | 9 (45.0) | 12 (40.0) | 14 (29.8) | 35 (36.1) |
No. of Bellmunt risk factors, n (%)e | ||||
 0 | 3 (15.0) | 6 (20.0) | 8 (17.0) | 17 (17.5) |
 1 | 9 (45.0) | 10 (33.3) | 23 (48.9) | 42 (43.3) |
 2 | 7 (35.0) | 11 (36.7) | 14 (29.8) | 32 (33.0) |
 3 | 1 (5.0) | 3 (10.0) | 2 (4.3) | 6 (6.2) |